User:Blent/Seminar 07 fall: Difference between revisions

From OpenWetWare
Jump to navigationJump to search
Line 21: Line 21:
* [http://www.nature.com/tpj/journal/v6/n4/full/6500356a.html A marker for Stevens-Johnson syndrome ...: ethnicity matters, The Pharmacogenomics Journal 2006]
* [http://www.nature.com/tpj/journal/v6/n4/full/6500356a.html A marker for Stevens-Johnson syndrome ...: ethnicity matters, The Pharmacogenomics Journal 2006]
** HLA-B 1502 may '''NOT''' be an universal marker for CBZ-SJS
** HLA-B 1502 may '''NOT''' be an universal marker for CBZ-SJS
* [http://www.nature.com/nrd/journal/v4/n1/full/nrd1605.html Genetic aspects of immune-mediated adverse drug effects, 2005 Nature]
* [http://www.nature.com/jid/journal/v114/n1/full/5600617a.html Nitric Oxide Synthase in Toxic Epidermal Necrolysis and Stevens–Johnson Syndrome, 2000 Journal of Investigative Dermatology]
* [http://sa.ylib.com/news/newsshow.asp?FDocNo=438&CL=28 嚴重藥物過敏,可以預防 (科學人 2004 May)]
* [http://sa.ylib.com/news/newsshow.asp?FDocNo=438&CL=28 嚴重藥物過敏,可以預防 (科學人 2004 May)]
* [http://explore.pts.org.tw/p2.htm 公視 探索未知世界 第二集: 解毒生命密碼-基因與藥物過敏]
* [http://explore.pts.org.tw/p2.htm 公視 探索未知世界 第二集: 解毒生命密碼-基因與藥物過敏]
Line 28: Line 30:
* [http://www.epochtimes.com/b5/7/9/18/n1837459.htm 台灣獨步全球 預防抗癲癇藥害 - 明年起先測基因 首見研究成果當警語 (大紀元電子報 9/18, 2007)]
* [http://www.epochtimes.com/b5/7/9/18/n1837459.htm 台灣獨步全球 預防抗癲癇藥害 - 明年起先測基因 首見研究成果當警語 (大紀元電子報 9/18, 2007)]
* [http://en.wikipedia.org/wiki/Carbamazepine Carbamazepine] is an long half-live drug
* [http://en.wikipedia.org/wiki/Carbamazepine Carbamazepine] is an long half-live drug
=== case study: Warfarin (抗凝血劑) and dosage estimation ===
=== case study: Warfarin (抗凝血劑) and dosage estimation ===
* [http://www.aafp.org/afp/990201ap/635.html Warfarin Therapy: Evolving Strategies in Anticoagulation, Feb 1999, American Family Physician]
* [http://www.aafp.org/afp/990201ap/635.html Warfarin Therapy: Evolving Strategies in Anticoagulation, Feb 1999, American Family Physician]

Revision as of 22:40, 1 October 2007

Title

  • Toward Personalized Medicine in BMI-based Methodology: A case study of Carbamazepine and challenges in the future

Outlines (Sep 30, 2007)

What is personalized medicine

case study: CBZ-SJS

case study: Warfarin (抗凝血劑) and dosage estimation

case study: Diabetes and Diagnosis

BioBank and Biomarkers discovery

case study: The First race-specific drug BiDil

ELSI, Biobank and FDA guide lines

Movies

Outlines (Sep 20, 2007)

  • BMI = BI + MI
    • what BMI can do
      • Neuroinformatics (NI)
      • Cancer research (CR)
  • Personalized Medicine (PM)

Background

Materials

Notes